Anti-Aging & Cellular Longevity
Educational map of GH secretagogues, pineal cytogens, and dermal peptides used in longevity folklore. Telomerase and “youthful gene expression” are not a US anti-aging indication.
Full stacking map, tiers, and monitoring notes live on the protocol page — this hub only lists the compounds already named for this goal.
Compounds on this goal
Epitalon
longevityKhavinson tetrapeptide (AEDG). Telomerase and fibroblast papers exist from that group. Not a US anti-aging NDA. Independent replication is thin.
Open peptide leaf →CJC-1295 (no DAC)
gh_secretagogueGHRH analog used for pulsatile GH. No-DAC vs DAC is a different week. Not somatropin.
Open peptide leaf →Ipamorelin
gh_secretagogueSelective ghrelin receptor (GHS-R1a) agonist used with a GHRH analog. Cortisol/prolactin sparing vs GHRP-6 is the usual selling point, not a cleanliness ranking.
Open peptide leaf →GHK-Cu
skinCopper tripeptide with Pickart microarray papers. "4,000+ genes" is expression-array marketing, not a wrinkle RCT or a US reconstruction indication.
Open peptide leaf →NAD+
longevityNAD+ is a cofactor. IV or research vials are not a sirtuin-restoration NDA. Percent-decline slides are not a protocol.
Open peptide leaf →NMN
mitochondrialOral NAD+ precursor identity. Not a peptide vial and not interchangeable with injectable NAD+ folklore on this hub.
Open peptide leaf →Urolithin A
mitochondrialMitophagy metabolite sold as an oral longevity ingredient. Not MOTS-c, not SS-31, not reconstitution math.
Open peptide leaf →Evidence note on this goal
Protocol evidence level (from existing goal data): Moderate
- Epithalon data primarily from one group (Khavinson); independent replication limited
- CJC-1295/Ipamorelin not FDA-approved; data from off-label clinical use
- Long-term telomerase activation safety requires further study (theoretical cancer risk)
- NAD+ delivery route significantly affects bioavailability; optimal method debated